637767-56-7

Upstream product

• 20989-17-7 (2S)-2-phenylglycinol 
• 637767-44-3 (1R,2R,5S,6S,7S)-2-(Allyl-benzyl-carbamoyl)-3-(4-methoxy-benzyl)-4-oxo-10-oxa-3-aza-tricyclo[5.2.1.0^1,5]dec-8-ene-6-carboxylic acid 
• 637767-24-9 (1R,2R,5S,6S,7S)-2-(Allyl-benzyl-carbamoyl)-3-(4-methoxy-benzyl)-4-oxo-10-oxa-3-aza-tricyclo[5.2.1.0^1,5]dec-8-ene-6-carboxylic acid (1R,2R)-2-(methyl-pent-4-enoyl-amino)-1-phenyl-propyl ester 

Downstream Products

• 637767-42-1 Pent-4-enoic acid (S)-2-{[(1R,2R,5S,6S,7S)-2-(allyl-benzyl-carbamoyl)-3-(4-methoxy-benzyl)-4-oxo-10-oxa-3-aza-tricyclo[5.2.1.0^1,5]dec-8-ene-6-carbonyl]-amino}-2-phenyl-ethyl ester 

Relevant academic research and scientific papers

Stereochemical Control of Skeletal Diversity

(Equation presented) Substrates having appendages that pre-encode skeletal information (σ-elements) can be converted into products having distinct skeletons using a common set of reaction conditions. The sequential use of the Ugi 4CC-IMDA reaction, followed by allylation, hydrolysis, and acylation of a chiral amino alcohol appendage (σ-element), leads to substrates for a ROM/RCM or RCM reaction. The stereochemistry of the a-element and not its constitution controls the outcome of the pathway selected. This work illustrates the potential of linking stereochemical control to the challenging problem of skeletal diversity.